Abstract
BackgroundAdoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) can mediate durable responses in advanced solid tumors.1–3 One of the challenges with current TIL productions is long duration of culture times...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
